FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975280344> ?p ?o ?g. }

• W2975280344 endingPage "3424" @default.
• W2975280344 startingPage "3419" @default.
• W2975280344 abstract "This study was performed to assess the efficacy and safety of apatinib in patients with metastatic or recurrent cervical cancer.Twenty-six patients with metastatic or recurrent cervical cancer and treated with apatinib until progressive disease or unacceptable toxicity were included in this multicenter, retrospective, observational study from January 2016 to April 2018. The primary end point was progression free survival (PFS). Secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and toxicity. Toxicities were assessed according to Common Terminology Criteria for Adverse Events.A total of 26 metastatic or recurrent cervical cancer patients were enrolled in this study. No complete response (CR) occurred, 4 patients (15.4%) showed partial response (PR), 11 patients (42.3%) had stable disease (SD), and 11 patients (42.3%) had progressive disease (PD), with DCR of 57.7% and ORR of 15.4%. Median progression-free survival (PFS) was 3.0 months (95% confidence interval [CI]: 0-6.3 months) and overall survival (OS) was 7.0 months (95% CI: 5.1-8.9 months) respectively. The most common adverse effects were hand-foot syndrome (50.0%), secondary hypertension (26.9%) and fatigue (26.9%). Three patients discontinued treatment due to grade 3 toxicities (one case for hand-foot syndrome, two cases for diarrhea) and 6 patients required dose reduction because of adverse effects.Apatinib seems active in heavily-pretreated metastatic or recurrent cervical cancer. The adverse effects were moderate but manageable." @default.
• W2975280344 created "2019-10-03" @default.
• W2975280344 creator A5008786007 @default.
• W2975280344 creator A5019149465 @default.
• W2975280344 creator A5019747633 @default.
• W2975280344 creator A5029667848 @default.
• W2975280344 creator A5046655494 @default.
• W2975280344 creator A5053427098 @default.
• W2975280344 creator A5080100220 @default.
• W2975280344 date "2019-09-01" @default.
• W2975280344 modified "2023-10-14" @default.
• W2975280344 title "<p>The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study</p>" @default.
• W2975280344 cites W1816099873 @default.
• W2975280344 cites W1968626722 @default.
• W2975280344 cites W1971837077 @default.
• W2975280344 cites W1977887541 @default.
• W2975280344 cites W1981186476 @default.
• W2975280344 cites W1986440851 @default.
• W2975280344 cites W1999966467 @default.
• W2975280344 cites W2003187434 @default.
• W2975280344 cites W2015919139 @default.
• W2975280344 cites W2019607817 @default.
• W2975280344 cites W2032995169 @default.
• W2975280344 cites W2050062343 @default.
• W2975280344 cites W2078397784 @default.
• W2975280344 cites W2100756525 @default.
• W2975280344 cites W2118508302 @default.
• W2975280344 cites W2142123446 @default.
• W2975280344 cites W2170825221 @default.
• W2975280344 cites W2272984102 @default.
• W2975280344 cites W2289495176 @default.
• W2975280344 cites W2761064712 @default.
• W2975280344 cites W2762884277 @default.
• W2975280344 cites W2779061198 @default.
• W2975280344 cites W2806333996 @default.
• W2975280344 cites W2886354380 @default.
• W2975280344 cites W2887865671 @default.
• W2975280344 cites W2917837889 @default.
• W2975280344 cites W4210281635 @default.
• W2975280344 doi "https://doi.org/10.2147/dddt.s214743" @default.
• W2975280344 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6769025" @default.
• W2975280344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31576114" @default.
• W2975280344 hasPublicationYear "2019" @default.
• W2975280344 type Work @default.
• W2975280344 sameAs 2975280344 @default.
• W2975280344 citedByCount "12" @default.
• W2975280344 countsByYear W29752803442019 @default.
• W2975280344 countsByYear W29752803442020 @default.
• W2975280344 countsByYear W29752803442021 @default.
• W2975280344 countsByYear W29752803442022 @default.
• W2975280344 countsByYear W29752803442023 @default.
• W2975280344 crossrefType "journal-article" @default.
• W2975280344 hasAuthorship W2975280344A5008786007 @default.
• W2975280344 hasAuthorship W2975280344A5019149465 @default.
• W2975280344 hasAuthorship W2975280344A5019747633 @default.
• W2975280344 hasAuthorship W2975280344A5029667848 @default.
• W2975280344 hasAuthorship W2975280344A5046655494 @default.
• W2975280344 hasAuthorship W2975280344A5053427098 @default.
• W2975280344 hasAuthorship W2975280344A5080100220 @default.
• W2975280344 hasBestOaLocation W29752803441 @default.
• W2975280344 hasConcept C121608353 @default.
• W2975280344 hasConcept C126322002 @default.
• W2975280344 hasConcept C141071460 @default.
• W2975280344 hasConcept C167135981 @default.
• W2975280344 hasConcept C197934379 @default.
• W2975280344 hasConcept C203092338 @default.
• W2975280344 hasConcept C2776694085 @default.
• W2975280344 hasConcept C2777793932 @default.
• W2975280344 hasConcept C2778220009 @default.
• W2975280344 hasConcept C2778822529 @default.
• W2975280344 hasConcept C2779134260 @default.
• W2975280344 hasConcept C2780668389 @default.
• W2975280344 hasConcept C2780739268 @default.
• W2975280344 hasConcept C535046627 @default.
• W2975280344 hasConcept C71924100 @default.
• W2975280344 hasConcept C90924648 @default.
• W2975280344 hasConceptScore W2975280344C121608353 @default.
• W2975280344 hasConceptScore W2975280344C126322002 @default.
• W2975280344 hasConceptScore W2975280344C141071460 @default.
• W2975280344 hasConceptScore W2975280344C167135981 @default.
• W2975280344 hasConceptScore W2975280344C197934379 @default.
• W2975280344 hasConceptScore W2975280344C203092338 @default.
• W2975280344 hasConceptScore W2975280344C2776694085 @default.
• W2975280344 hasConceptScore W2975280344C2777793932 @default.
• W2975280344 hasConceptScore W2975280344C2778220009 @default.
• W2975280344 hasConceptScore W2975280344C2778822529 @default.
• W2975280344 hasConceptScore W2975280344C2779134260 @default.
• W2975280344 hasConceptScore W2975280344C2780668389 @default.
• W2975280344 hasConceptScore W2975280344C2780739268 @default.
• W2975280344 hasConceptScore W2975280344C535046627 @default.
• W2975280344 hasConceptScore W2975280344C71924100 @default.
• W2975280344 hasConceptScore W2975280344C90924648 @default.
• W2975280344 hasLocation W29752803441 @default.
• W2975280344 hasLocation W29752803442 @default.
• W2975280344 hasLocation W29752803443 @default.
• W2975280344 hasLocation W29752803444 @default.
• W2975280344 hasOpenAccess W2975280344 @default.
• W2975280344 hasPrimaryLocation W29752803441 @default.

• next